Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection Medical Dialogues Bureau12 April 2020 1:30 PM ISTVazegepant is currently advancing to Phase 3 development for the acute treatment of migraines in adults under the Division of Neurology, having...